Advertisement

Search Results

Advertisement



Your search for ,maY matches 16442 pages

Showing 3351 - 3400


lung cancer
immunotherapy

Expert Point of View: Edward B. Garon, MD

Invited discussant of the NeoCOAST trial, Edward B. Garon, MD, Professor of Medicine and Director of the Thoracic Oncology Program at David Geffen School of Medicine at the University of California Los Angeles, praised the study: “NeoCOAST is an impressive study that showed numerical benefit when...

lung cancer
immunotherapy

Novel Neoadjuvant Therapy May Boost Response in Resectable NSCLC

Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC), according to the results of the phase II NeoCOAST trial presented at the American Association for Cancer Research (AACR)...

breast cancer

An Early Love of Science Led to a Career in Breast Cancer Research for Sara M. Tolaney, MD, MPH

In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Sara M. Tolaney, MD, MPH, a faculty member of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she is Chief of the Breast Cancer Program. Her current research focuses on the development of novel ...

gynecologic cancers

Combination Therapy of Olaparib, Cyclophosphamide, and Metformin Under Study in Advanced Endometrial Cancer

A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...

breast cancer

[F-18]FES-PET Assessment of ER Status in Metastases From Newly Diagnosed Patients With Metastatic Breast Cancer

In a subanalysis from the Dutch IMPACT-MBC study reported in the Journal of Clinical Oncology, van Geel et al found that qualitative whole-body 16α-[fluorine F-18]fluoro-17β-estradiol positron-emission tomography/computed tomography ([F-18]FES-PET) was highly accurate in predicting estrogen...

hepatobiliary cancer

Radiation Segmentectomy for Very Early– and Early-Stage Hepatocellular Carcinoma

Radiation segmentectomy may be an effective treatment for very early– to early-stage hepatocellular carcinoma (HCC) that cannot be treated surgically or thermally. The findings from a multidisciplinary study by researchers at the Icahn School of Medicine at Mount Sinai were published by Kim et al...

colorectal cancer

Study Finds Screen-Detected Colorectal Cancers May Have More Favorable Stage Distribution Than Colorectal Cancers Detected Otherwise

In a population-based study conducted in nine European countries for which data on mode of detection were available (Belgium, Denmark, England, France, Italy, Ireland, the Netherlands, Slovenia, and Spain), the proportion of colorectal cancer cases detected by screening varied widely between...

head and neck cancer
pain management

Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation

Patients with head and neck cancer undergoing radiation therapy may be less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, findings from a team of radiation oncologists showed. Their report, published by Ma et al in JAMA ...

prostate cancer

Does Treatment With 5α-Reductase Inhibitors Impact the Risk of Dying of Prostate Cancer Among Men Without a Prior Diagnosis of the Disease?

In a Swedish study reported in JAMA Oncology, Björnebo et al found that longer use of 5α-reductase inhibitors (5-ARIs) for the treatment of benign prostatic hyperplasia was associated with a reduced risk of prostate cancer mortality among men without a prior diagnosis of prostate cancer. As stated...

skin cancer
immunotherapy

Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma

Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...

skin cancer
immunotherapy

Approaches to Potentiate Immune Response in Patients Who Do Not Respond to Anti–PD-1 Therapy for Melanoma

A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...

breast cancer

EMERALD Trial: Elacestrant vs Standard Endocrine Therapy in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor (ER) degrader elacestrant vs standard endocrine therapy among patients with...

lung cancer

Tazemetostat for Patients With Relapsed or Refractory BAP1-Inactivated Malignant Pleural Mesothelioma

In a phase II study reported in The Lancet Oncology, Zauderer et al found that the EZH2 inhibitor tazemetostat was active in patients with relapsed or refractory BRCA-associated protein 1 (BAP1)-inactivated malignant pleural mesothelioma. As noted by the investigators, high expression of EZH2 has...

prostate cancer
symptom management

Adverse Events Seen With Abiraterone or Enzalutamide Among Patients With Advanced Prostate Cancer

Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were receiving hormone therapy alone, according to findings...

lung cancer

Report Examines Imaging Approach With Potential to Detect Lung Cancer at the Cellular Level

Researchers have found a way to identify lung cancer at the cellular level in real time during a biopsy, which may enable detection of the disease earlier and with more confidence. The findings, published by Kennedy et al in Nature Communications, demonstrated that an imaging agent detected via...

leukemia

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

On May 20, the U.S. Food and Drug Administration approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). AZA-JMML-001 Efficacy was evaluated in AZA-JMML-001 (ClinicalTrials.gov identifier NCT02447666), an international, multicenter,...

issues in oncology

Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials

Two oncologists who are now heads of oncology development for pharmaceutical companies discussed the future of cancer drugs at the Community Oncology Alliance’s 2022 Community Oncology Conference. They were ­Johanna Bendell, MD, Global Head of Oncology, Pharma Research, and Early Development at...

issues in oncology

Researchers Develop and Monitor Approaches to Fix Blood Vessel Abnormalities That Make Tumors Difficult to Treat

Tumors send out signals that impair normal blood flow, which makes them hard to treat with multiple therapies, including radiation, chemotherapy, targeted therapies, and immunotherapy. Impaired blood supply creates an environment low in oxygen levels, which causes the tumors to take on aggressive...

issues in oncology

ASCO and ACCC Release Wide-Ranging Recommendations to Expand Diverse Participation in Cancer Clinical Trials

ASCO and the Association of Community Cancer Centers (ACCC) have jointly released recommendations that address the lack of equity, diversity, and inclusion in cancer clinical trials. Published by Randall A. Oyer, MD, and colleagues in the Journal of Clinical Oncology, the research statement details ...

covid-19

Mortality and Associated Factors Among Patients With Cancer vs No Cancer Infected With SARS–CoV-2

In a systematic review and meta-analysis reported in JAMA Network Open, Khoury et al found that SARS­­–CoV-2 infection was associated with a higher risk of mortality among patients with cancer vs those without cancer. Risk vs those with no cancer was increased with younger age, and patients with...

breast cancer

Intraoperative Margin Assessment in Breast-Conserving Surgery Using a Pegulicianine Fluorescence–Guided System

In the INSITE study reported in JAMA Surgery, E. Shelley Hwang, MD, MPH, and colleagues found that use of an intraoperative imaging agent with a pegulicianine fluorescence–guided system (pFGS) was effective in detecting residual cancer in the tumor bed of women with breast cancer undergoing...

breast cancer

Surgery Preference and Surgery Received in Women With DCIS

In an ancillary study of the ECOG-ACRIN Cancer Research Group E4112 study reported in JAMA Network Open, Fazeli et al found that patient preference of type of surgery and type of surgery received for ductal carcinoma in situ (DCIS) were influenced by preoperative magnetic resonance imaging (MRI)...

gastrointestinal cancer
breast cancer
survivorship
multiple myeloma
lymphoma

NCCN Clinical Practice Guidelines in Oncology: 2022 Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...

breast cancer

Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases

As reported in JAMA Oncology by Debu Tripathy, MD, and colleagues, the phase III ATTAIN trial has shown no difference in overall survival with etirinotecan pegol vs physician’s choice of chemotherapy for patients with metastatic breast cancer and brain metastases. As noted by the investigators,...

genomics/genetics

Study Points to Expanded Genomic Testing to Benefit Children and Young Adults With Cancer

New findings from researchers at Memorial Sloan Kettering Cancer Center published by Shukla et al in Nature Communications reported the results of using a comprehensive sequencing approach on 114 pediatric, adolescent, and young adult patients with solid tumors. The researchers found that their...

hepatobiliary cancer

Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Multifocal Intrahepatic Cholangiocarcinoma

In a cohort study reported in JAMA Surgery, Franssen et al found little difference in median overall survival with hepatic arterial infusion pump (HAIP) floxuridine chemotherapy vs resection in patients with multifocal intrahepatic cholangiocarcinoma. Study Details The study population consisted of ...

legislation

Medicaid Expansion Is Associated With Increased Survival in Newly Diagnosed Patients With Cancer

A large study led by researchers at the American Cancer Society showed that Medicaid expansion under the Affordable Care Act (ACA) was associated with an increase in 2-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people...

leukemia
multiple myeloma

Using a Transcriptomic Profile to Identify Plasma Cell Leukemia–Like Disease in Patients With Newly Diagnosed Multiple Myeloma

In a study reported in the Journal of Clinical Oncology, Bruinink et al constructed a transcriptomic classifier for primary plasma cell leukemia (PCL) that identified high-risk PCL-like disease in patients with newly diagnosed multiple myeloma. As stated by the investigators, “Primary PCL is an...

lung cancer
genomics/genetics

Matthew L. Meyerson, MD, PhD, on Lung Adenocarcinoma: Somatic Mutations, Germline Risk, and Ancestry

Matthew L. Meyerson, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings that suggest the variation in frequency of EGFR and KRAS mutations in lung cancer may be associated with genetic ancestry in patients from Latin America. The results indicate it may be possible to identify...

issues in oncology

The Future of Community Oncology Practice

Although community oncology practice may have been changing before the COVID-19 pandemic, it amplified industry trends. At the 2022 Community Oncology Alliance’s Community Oncology Conference, a panel of experts discussed issues related to the future of community cancer care, including...

bladder cancer
immunotherapy

Longer Follow-up Shows Adjuvant Immunotherapy After Bladder Cancer Surgery May Be Associated With Reduced Disease Recurrence

Treatment with the anti–PD-1 therapy nivolumab after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results...

breast cancer

Study Investigates Possible Link Between Risk of Breast Cancer in Males and Male Infertility

The risk of invasive breast cancer in men may be associated with self-reported infertility, according to a study published by Swerdlow et al in the journal Breast Cancer Research. The authors interviewed 1,998 males in England and Wales diagnosed with breast cancer, with 112 (5.6%) also...

pancreatic cancer

Early Postoperative Algorithm-Based vs Usual Care After Pancreatic Resection

In a Dutch nationwide trial reported by Smits et al in The Lancet, researchers in the Dutch Pancreatic Cancer Group found that algorithm-based early postsurgical care was associated with a reduced risk of the composite outcome of bleeding requiring invasive intervention, organ failure, and 90-day...

breast cancer

Do Electronic Health Interventions Improve Quality of Life and Other Health Outcomes in Patients With Breast Cancer?

In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Singleton et al found that electronic health interventions were associated with improved quality of life, distress, self-efficacy, and fatigue vs usual care during or after treatment in patients with breast...

breast cancer

Guideline-Concordant Treatment of Women With Nonmetastatic Breast Cancer in Sub-Saharan Africa

As reported in The Lancet Oncology by Foerster et al, the African Breast Cancer–Disparities in Outcomes prospective cohort study has shown that a high proportion of women with newly diagnosed nonmetastatic breast cancer in sub-Saharan Africa did not initiate, did not fully complete, or abandoned...

covid-19

CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer

CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related immunoglobulin deficiency in a phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 These patients are...

colorectal cancer

Colonoscopy After Positive FIT Test May Reduce Risk of Death From Colorectal Cancer

Recent research underlines the importance of following up with a colonoscopy exam after a positive result on an at-home stool test to screen for colorectal cancer. The test, known as the fecal immunochemical test (FIT), checks for traces of blood in patient-collected stool samples, which can be an...

bladder cancer
genomics/genetics

Report Finds Uptake of Erdafitinib for Urothelial Cancer May Be Limited, Despite Positive Real-World Survival Data

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a report published as a research letter by Nimgaonkar et al in JAMA Oncology. Researchers analyzed a large, nationwide database of cancer...

prostate cancer

Addition of ADT and Pelvic Lymph Node Radiotherapy to Salvage Prostate Bed Radiotherapy After Prostatectomy

In a phase III trial (NRG Oncology/RTOG 0534 SPPORT) reported in The Lancet, Alan Pollack, MD, PhD, and colleagues found that both the addition of short-term androgen-deprivation therapy (ADT) and the addition of ADT and pelvic lymph node radiotherapy (PLNRT) to salvage prostate bed radiotherapy...

gynecologic cancers

Addition of Vistusertib to Anastrozole for Hormone Receptor–Positive Recurrent or Metastatic Endometrial Cancer

In a French phase I/II trial (VICTORIA) reported in JAMA Oncology, Heudel et al found that the addition of the mTOR inhibitor vistusertib to anastrozole improved outcomes in women with hormone receptor–positive recurrent or metastatic endometrial cancer. As stated by the investigators, “Endometrial ...

cns cancers

Neurologic and Survival Outcomes After Awake Craniotomy for Glioblastoma

In an analysis from the GLIOMAP study reported in The Lancet Oncology, Gerritsen et al found that awake craniotomy for glioblastoma in eloquent brain areas (essential areas for carrying out basic neurological functions) was associated with reduced risk of neurologic deficits and improved survival...

gynecologic cancers

Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery

Pedro T. Ramirez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final analysis of the LACC trial (Laparoscopic Approach to Cervical Cancer), which showed that women with early cervical cancer who need a radical hysterectomy may have worse outcomes with minimally invasive...

solid tumors
genomics/genetics

Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors

The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...

gastroesophageal cancer
covid-19

Delays in Surgery for Advanced Esophageal Cancer Result in Significantly Worse Survival

Delays in surgery for esophageal cancer did not appear to have much impact on patients’ relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an...

lymphoma
immunotherapy

Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma

A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...

colorectal cancer

Watch-and-Wait Strategy for Organ Preservation in Patients Receiving Total Neoadjuvant Therapy for Rectal Adenocarcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Garcia-Aguilar et al found that total neoadjuvant therapy followed by a watch-and-wait strategy vs total mesorectal excision based on response allowed for organ preservation in approximately half of patients with rectal...

leukemia
survivorship

AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population

Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...

issues in oncology
survivorship

Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors

Maria Alma Rodriguez, MD, of The University of Texas MD Anderson Cancer Center, discusses the need for various types of vaccinations in patients with cancer, who are vulnerable to infection while under active treatment and whose immune deficits may persist long after treatment is finished. Dr....

prostate cancer

Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer

The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...

hematologic malignancies
multiple myeloma
lymphoma
leukemia

Prevalence of Plasma Cell and Lymphoproliferative Disorders in Relatives of Probands With Light Chain Amyloidosis

In a study reported in the British Journal of Haematology, Staron et al found that the prevalence of plasma cell and lymphoproliferative disorders among blood relatives of probands with light chain (AL) amyloidosis was low overall and varied according to proband AL amyloidosis subtype. Despite...

Advertisement

Advertisement




Advertisement